Ramin Farzaneh-Far Sells 10,595 Shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) Stock

Ra Pharmaceuticals Inc (NASDAQ:RARX) insider Ramin Farzaneh-Far sold 10,595 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $46.89, for a total transaction of $496,799.55. Following the completion of the sale, the insider now owns 8,521 shares in the company, valued at $399,549.69. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Ramin Farzaneh-Far also recently made the following trade(s):

  • On Monday, September 16th, Ramin Farzaneh-Far sold 10,595 shares of Ra Pharmaceuticals stock. The shares were sold at an average price of $25.26, for a total transaction of $267,629.70.

Shares of Ra Pharmaceuticals stock traded down $0.12 during midday trading on Thursday, hitting $46.54. The company had a trading volume of 255,421 shares, compared to its average volume of 624,098. The stock has a market cap of $2.21 billion, a price-to-earnings ratio of -22.59 and a beta of 1.34. The company has a quick ratio of 15.30, a current ratio of 15.30 and a debt-to-equity ratio of 0.02. The company has a fifty day simple moving average of $28.67 and a 200 day simple moving average of $27.01. Ra Pharmaceuticals Inc has a 12-month low of $11.27 and a 12-month high of $47.08.

Ra Pharmaceuticals (NASDAQ:RARX) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.03). As a group, analysts expect that Ra Pharmaceuticals Inc will post -1.98 EPS for the current year.

RARX has been the topic of a number of recent analyst reports. Royal Bank of Canada restated a “sector perform” rating and issued a $48.00 price target on shares of Ra Pharmaceuticals in a report on Friday, October 11th. Credit Suisse Group cut shares of Ra Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Tuesday. Raymond James cut shares of Ra Pharmaceuticals from a “strong-buy” rating to a “market perform” rating in a report on Monday, July 29th. BMO Capital Markets cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $48.00 price target on the stock. in a report on Thursday, October 10th. Finally, Svb Leerink cut shares of Ra Pharmaceuticals from an “outperform” rating to a “market perform” rating and raised their price target for the company from $38.00 to $48.00 in a report on Friday, October 11th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the company’s stock. Ra Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $44.25.

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its position in shares of Ra Pharmaceuticals by 27.9% in the 2nd quarter. BlackRock Inc. now owns 4,059,169 shares of the company’s stock valued at $122,061,000 after purchasing an additional 886,583 shares during the last quarter. Vanguard Group Inc. raised its position in Ra Pharmaceuticals by 19.4% in the second quarter. Vanguard Group Inc. now owns 1,564,112 shares of the company’s stock worth $47,033,000 after acquiring an additional 253,966 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in Ra Pharmaceuticals by 15.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 1,178,000 shares of the company’s stock worth $35,267,000 after acquiring an additional 154,000 shares in the last quarter. VHCP Management II LLC raised its position in Ra Pharmaceuticals by 7.1% in the second quarter. VHCP Management II LLC now owns 677,164 shares of the company’s stock worth $20,362,000 after acquiring an additional 44,684 shares in the last quarter. Finally, VHCP Management III LLC raised its position in Ra Pharmaceuticals by 12.7% in the second quarter. VHCP Management III LLC now owns 670,350 shares of the company’s stock worth $20,157,000 after acquiring an additional 75,637 shares in the last quarter. 91.59% of the stock is owned by hedge funds and other institutional investors.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Read More: Golden Cross

Insider Buying and Selling by Quarter for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.